Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax

In SilicoModeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer Therapy

(2015) Rama K. Mishra et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

(2015) J D Leverson et al.   Cell Death & Disease

Antagonizing Bcl-2 Family Members Sensitizes Neuroblastoma and Ewing’s Sarcoma to an Inhibitor of Glutamine Metabolism

(2015) Rachelle R. Olsen et al.   PLoS One

A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance

(2014) Z. Liu et al.   BLOOD

Curing myeloma at last: defining criteria and providing the evidence

(2014) B. Barlogie et al.   BLOOD

Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin

(2014) S. Dalva-Aydemir et al.   CLINICAL CANCER RESEARCH

Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer

(2014) M. I. Gross et al.   MOLECULAR CANCER THERAPEUTICS

Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer

(2014) W Nakajima et al.   Cell Death & Disease

Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure

(2013) R. L. Thomas et al.   GENES & DEVELOPMENT

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma

(2013) C Touzeau et al.   LEUKEMIA

Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway

(2013) Jaekyoung Son et al.   NATURE

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy

(2012) S. K. McBrayer et al.   BLOOD

Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML

(2012) Thanh-Trang Vo et al.   CELL

Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death

(2012) Nicholas A Graham et al.   Molecular Systems Biology

Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells

(2011) A. A. Morales et al.   BLOOD

Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets

(2011) S. M. Schoenwaelder et al.   BLOOD

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy

(2011) T. N. Chonghaile et al.   SCIENCE

Apoptosis Threshold Set by Noxa and Mcl-1 after T Cell Activation Regulates Competitive Selection of High-Affinity Clones

(2010) Felix M. Wensveen et al.   IMMUNITY

Akt Requires Glucose Metabolism to Suppress Puma Expression and Prevent Apoptosis of Leukemic T Cells

(2010) Jonathan L. Coloff et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Effects of the HIV Protease Inhibitor Ritonavir on GLUT4 Knock-out Mice

(2010) Arpita Kalla Vyas et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

(2010) Wyndham H Wilson et al.   LANCET ONCOLOGY

Characterization of Puma-Dependent and Puma-Independent Neuronal Cell Death Pathways following Prolonged Proteasomal Inhibition

(2010) L. P. Tuffy et al.   MOLECULAR AND CELLULAR BIOLOGY

F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma

(2009) T. B. Bartel et al.   BLOOD

Targeting Glucose Consumption and Autophagy in Myeloma with the Novel Nucleoside Analogue 8-Aminoadenosine

(2009) Mala Shanmugam et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines

(2009) T. Eguchi et al.   MOLECULAR CANCER THERAPEUTICS

Mimicking the BH3 domain to kill cancer cells

(2009) T Ni Chonghaile et al.   ONCOGENE

Glycolysis inhibition sensitizes tumor cells to death receptors-induced apoptosis by AMP kinase activation leading to Mcl-1 block in translation

(2009) L A Pradelli et al.   ONCOGENE

Functional and Structural Characterization of Four Glutaminases from Escherichia coli and Bacillus subtilis†

(2008) Greg Brown et al.   BIOCHEMISTRY

BCL-2 family antagonists for cancer therapy

(2008) Guillaume Lessene et al.   NATURE REVIEWS DRUG DISCOVERY

mTORC1 promotes survival through translational control of Mcl-1

(2008) J. R. Mills et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA